Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.
Here's a round up of Vantage's coverage of the 2020 European Society for Medical Oncology congress.
The company is one of very few to have studied combining PD-1 and PD-L1 blockade, an approach still in need of scientific validation.
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.
The Merck & Co drug looks to extend its position in a biomarker-defined colorectal cancer niche, but is it too early to declare victory?